Atazanavir & Ritonavir

Atazanavir & Ritonavir

Form: Tablets

Strength: 300 mg Atazanavir + 100 mg Ritonavir

Reference Brands: Evotaz®(US)

Category: Anti Viral

Atazanavir & Ritonavir Tablets are a fixed-dose antiretroviral combination used in the management of HIV-1 infection, with Ritonavir boosting Atazanavir’s effectiveness. Available in a 300 mg + 100 mg formulation, this once-daily therapy is WHO-recommended and USFDA-approved. On PharmaB2B platforms, global buyers can connect with GMP-certified manufacturers for bulk procurement of quality-assured Atazanavir/Ritonavir tablets. Ideal for hospitals, NGOs, government tenders, and HIV treatment programs, PharmaB2B simplifies sourcing of affordable, compliant ARVs. Partner with reliable suppliers to support uninterrupted access to essential HIV care in both regulated and emerging markets.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Zanamivir

Strength: 5 mg/blister

Form: Inhalation powder

Reference Brands: Relenza(EU & US)

View Details Get Enquiry
Oseltamivir Phosphate Capsule

Strength: Capsule- 30 mg, 45 mg, 75 mg; Oral Suspension - 6 mg/mL (reconstituted)

Form: Capsules and Oral solution

Reference Brands: Tamiflu(EU & US)

View Details Get Enquiry
Amantadine

Strength: Tab -100 mg; Capsule- 100 mg; Oral solution - 50 mg/5 mL; Extended-release capsule (ER) - 129 mg, 193 mg

Form: Tablet; Capsule; Oral Solution and ER Capsule

Reference Brands: Symmetrel(EU & US); Osmolex ER(US), Gocovri(US)

View Details Get Enquiry
Glecaprevir + Pibrentasvir

Strength: Glecaprevir- 100 mg + Pibrentasvir - 40 mg

Form: Tablet

Reference Brands: Mavyret (US); Maviret (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.